Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Recipient : Fertin Pharma AS
Deal Size : $820.0 million
Deal Type : Acquisition
Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 15, 2021
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : Fertin Pharma AS
Deal Size : $820.0 million
Deal Type : Acquisition
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : OtiTopic
Deal Size : Undisclosed
Deal Type : Acquisition
Philip Morris International Acquires Inhaled Drug Specialist OtiTopic
Details : OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. The company expects to move from clinical trials of Asprihale to filing for FDA approval at some point in 20...
Brand Name : Asprihale
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : OtiTopic
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Recipient : Fertin Pharma AS
Deal Size : $820.0 million
Deal Type : Acquisition
Philip Morris International Announces Agreement to Acquire Fertin Pharma
Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : Fertin Pharma AS
Deal Size : $820.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?